The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy

Publication: Annals of Surgical Oncology, Sept 1 2023 Authors: Peter Blumencranz MD, FACS, Mehran Habibi MD, Steve Shivers PhD, Geza Acs MD, Lisa E. Blumencranz PhD, Erin B. Yoder MS, Bastiaan van der Baan MS, Andrea R. Menicucci PhD, Patricia Dauer PhD, William Audeh MD & Charles E. Cox MD

Read More
2024-11-29T15:26:47-05:00September 5th, 2023|Evidence, MINT, Neoadjuvant|

MammaPrint and BluePrint as prognostic indicators for elderly patients with early-stage breast cancer

PUBLICATION: SABCS 2020 AUTHORS: Peter W. Blumencranz, Mehran Habibi, Read More

2024-03-25T08:05:58-04:00December 29th, 2020|Adjuvant, Evidence, MINT, Neoadjuvant|
Go to Top